Literature DB >> 6502493

Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats.

D Leu, B Manthey, J Kreuter, P Speiser, P P DeLuca.   

Abstract

Surfactant-coated polymethyl [2-14C]methacrylate nanoparticles had significantly different time-course distribution patterns in rats than noncoated and albumin-coated particles. Blood concentrations of poloxamer 188-coated particles were 70-fold higher after 30 min, and the particles persisted at higher levels in the circulation for up to 2 h. The initial and final liver levels were significantly lower (38% after 30 min, 51% after 7 d) and spleen levels were significantly higher (21% after 30 min, 23% after 7 d) than non-coated particles (74% in the liver and 5% in the spleen after 7 d) and the albumin-coated particles (84% in the liver and 5% in the spleen after 7 d). Specific activity was somewhat higher for the surfactant-coated particles in other organs such as the lungs, kidneys, testicles, ovaries, and lymph nodes. The bovine serum albumin sorption behavior of polymethyl methacrylate nanoparticles was followed under various conditions, and adsorption was found to increase with increasing protein concentration and increasing temperature, reaching a maximum at the isoelectric point of pH 4.9 after approximately 12 h of incubation. The zeta potential of the particles decreased with increasing pH, and the change was more pronounced with the albumin-coated particles.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502493     DOI: 10.1002/jps.2600731028

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

2.  Prolonged blood circulation in rats of nanospheres surface-modified with semitelechelic poly[N-(2-hydroxypropyl)methacrylamide].

Authors:  S Kamei; J Kopecek
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

3.  Direct suppression of phagocytosis by amphipathic polymeric surfactants.

Authors:  N Watrous-Peltier; J Uhl; V Steel; L Brophy; E Merisko-Liversidge
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

4.  Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting.

Authors:  V Schäfer; H von Briesen; R Andreesen; A M Steffan; C Royer; S Tröster; J Kreuter; H Rübsamen-Waigmann
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

5.  Effect of surface properties of silica nanoparticles on their cytotoxicity and cellular distribution in murine macrophages.

Authors:  Hiromi Nabeshi; Tomoaki Yoshikawa; Akihiro Arimori; Tokuyuki Yoshida; Saeko Tochigi; Toshiro Hirai; Takanori Akase; Kazuya Nagano; Yasuhiro Abe; Haruhiko Kamada; Shin-Ichi Tsunoda; Norio Itoh; Yasuo Yoshioka; Yasuo Tsutsumi
Journal:  Nanoscale Res Lett       Date:  2011-01-18       Impact factor: 4.703

Review 6.  Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity.

Authors:  Yeon Kyung Lee; Eun-Ju Choi; Thomas J Webster; Sang-Hyun Kim; Dongwoo Khang
Journal:  Int J Nanomedicine       Date:  2014-12-18

7.  Phosphatidylserine targets single-walled carbon nanotubes to professional phagocytes in vitro and in vivo.

Authors:  Nagarjun V Konduru; Yulia Y Tyurina; Weihong Feng; Liana V Basova; Natalia A Belikova; Hülya Bayir; Katherine Clark; Marc Rubin; Donna Stolz; Helen Vallhov; Annika Scheynius; Erika Witasp; Bengt Fadeel; Padmakar D Kichambare; Alexander Star; Elena R Kisin; Ashley R Murray; Anna A Shvedova; Valerian E Kagan
Journal:  PLoS One       Date:  2009-02-09       Impact factor: 3.240

8.  Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems.

Authors:  Neill J Liptrott; Marco Giardiello; Tom O McDonald; Steve P Rannard; Andrew Owen
Journal:  J Nanobiotechnology       Date:  2018-03-15       Impact factor: 10.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.